BioCardia’s data safety monitoring board already warned that the phase 3 CardiAMP cell therapy heart failure trial was not going to make the primary endpoint. And so the California biotech is ...
Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...
Results from the first randomised trial evaluating microRNA inhibition in heart failure were presented today at Heart Failure 2026.
Oliguric renal failure is a phase of acute renal failure (ARF), also known as acute kidney injury (AKI), in which a person’s urine output is very low. ARF is a sudden decline in kidney functioning.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results